Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.29%38.060.9%$1107.43m
JNJJohnson & Johnson 0.14%148.210.7%$820.15m
MRKMerck & Co., Inc. -0.08%83.470.7%$646.78m
ABBVAbbVie, Inc. 0.42%95.081.9%$619.40m
BMYBristol-Myers Squibb Co. -0.14%63.151.0%$617.68m
AZNAstraZeneca Plc -1.08%55.201.2%$504.65m
LLYEli Lilly & Co. -0.25%150.091.1%$396.64m
NVSNovartis AG -0.84%84.650.2%$154.29m
GSKGlaxoSmithKline Plc -1.55%40.550.2%$129.26m
MISTMilestone Pharmaceuticals, Inc. -2.17%8.550.0%$117.60m
OPKOPKO Health, Inc. -1.13%4.8011.2%$113.10m
NVONovo Nordisk A/S -0.85%65.780.1%$68.42m
RGENRepligen Corp. -1.62%143.897.1%$65.57m
IMRNImmuron Ltd. 9.27%11.080.0%$54.00m
SNYSanofi -2.03%50.330.2%$53.85m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.